DrugDashboards

Pantoprazole sodium

Pantoprazole sodium · PANTOPRAZOLE SODIUM 40 mg/10mL · Injection, Powder, For Solution · Intravenous · BE Pharmaceuticals Inc.

NDC 71839-0122-10 · 10 CARTON in 1 PACKAGE / 1 VIAL in 1 CARTON / 10 mL in 1 VIAL · ANDA · View full market →

The short version

13 companies supply this market — deep enough that no single failure threatens the supply. The price is up 15% over the past year, to $2.37 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.7% of the time — roughly 4× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$2.37per EAinvoice-surveyed acquisition cost · Mar 18, 2026
  • Part D plans paid (avg)$0.1987per dosage unitgross, before rebates — matched by drug name · 2024

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$2.00$4.00Apr 2024Sep 2026$2.37
18 price points · per EA · held since Mar 18, 2026Source: CMS NADAC

Estimated fill cost

WAC per package, as filed
$44.50
Reported to Texas DSHS · 2026 annual filing · BE Pharmaceuticals, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2023)

$1,194
33 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

10● Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.7%chance of a new FDA shortage posting for pantoprazole sodium (injectable) in the next 90 days

sterile injectable · price up 28% YoY · OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $12.94 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA216171
TE code
AP
Approval date
May 18, 2022
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedSep 5, 2023
    BE PHARMACEUTICALS AG — Lack of Assurance of Sterility: Powder discoloration due to small crack in some vials.

Manufacturers of Pantoprazole sodium (Injection, Powder, For Solution)

LabelerStrengthFirst seenLast seen
Meitheal Pharmaceuticals Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 3, 2026
BE Pharmaceuticals Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.PANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Devatis Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Eugia US LLCPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Northstar Rx LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Novadoz Pharmaceuticals LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Piramal Critical CarePANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Sandoz IncPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Takeda GmbHPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Wasserburger Arzneimittelwerk GmbHPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Pantoprazole sodium — NDC 71839-0122-10," retrieved September 3, 2026, https://drugdashboards.com/drug/71839012210.

Free to cite with attribution — see how the data is put together.